
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings demonstrates significant positive momentum in its operations, with year-over-year growth reported in its Functional Service Provider (FSP), Real World Evidence (RWE), and Commercial Services and Medical Solutions (CSMS) segments during the third quarter. The company has improved client decision timelines and maintains a strong pipeline, which bodes well for its commercial solutions segment, particularly driven by recent drug launches. Furthermore, IQVIA anticipates a growth rate exceeding 4% in its Research and Development Solutions segment on a constant currency basis, supported by an improved pricing environment that allows the company to selectively engage in high-value deals.
Bears say
The financial outlook for IQVIA Holdings reflects a decline in year-over-year constant currency growth, decreasing to 3.8% from 6.8% in the previous period, attributed to challenging year-over-year comparisons and a specific growth figure of 8.6% from the earlier year. Despite assurances from the company that it does not foresee a regression in revenue growth for 2026, there are concerns about its ability to maintain positive growth levels, with expectations set at a minimum of 5% growth. Additionally, operational issues such as zero margin passthroughs and the potential negative impact of rising interest rates on earnings further exacerbate uncertainties surrounding the company's financial performance.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares